School of Medicine
Showing 491-500 of 511 Results
-
Jingru Yu
Postdoctoral Scholar, Pathology
BioJingru Yu, PhD, MPH, is a postdoctoral researcher at the Department of Pathology. She is interested in developing early diagnostic tools for brain tumors and other solid tumors using epigenomic data and aims to improve the diagnosis and prognosis of tumors.
-
Kelley Yuan
Affiliate, Department Funds
Resident in PathologyCurrent Research and Scholarly InterestsPlayfulness
Decision-making
Trust -
Muharrem Yunce, M.D.
Clinical Associate Professor, Pathology
BioDr. Yunce completed his transfusion medicine fellowship at Stanford and then gained invaluable clinical experience with the Malignant Hematology Group at UCSF for two years. After rejoining Stanford, Dr. Yunce started as the Medical Director of Therapeutic Apheresis. In this role, he works with the nursing and medical staff to ensure life-saving and emergent procedures such as therapeutic plasma exchange (TPE), red cell exchange, plateletpheresis, and leukapheresis are conducted effectively. Additionally, Dr. Yunce oversees extracorporeal photopheresis for solid organ transplant rejection.
Dr. Yunce is also a well-recognized teaching faculty member in the Department of Pathology. He was honored with the Teaching Award in 2023 by the department and was nominated in 2023 and 2024 for the prestigious Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care.
As an active member of the American Society of Apheresis, Dr. Yunce chairs the research subcommittee on TPE utilization in solid organ transplant rejection and desensitization protocols as well as member of multiple research subcommittees. -
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
On Leave from 09/01/2024 To 11/01/2024Current Research and Scholarly InterestsMy main research and clinical interests include molecular pathogenesis of acquired cytopenias, genetic testing for inherited non-malignant hematologic disorders, next-generation sequencing approaches to T and B cell clonality testing, somatic mutations in cancer and assessment of minimal residual disease in cancer patients.
